These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11869410)

  • 21. Risperidone-induced sexual dysfunction in a prepubertal child - a case report.
    Wadoo O; Chalhoub N
    J Psychopharmacol; 2009 Aug; 23(6):727-8. PubMed ID: 18562402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Lu ML; Shen WW
    Ann Pharmacother; 2002; 36(7-8):1292; author reply 1292-3. PubMed ID: 12086567
    [No Abstract]   [Full Text] [Related]  

  • 23. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
    Haas M; Karcher K; Pandina GJ
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hyperprolactinemia in a child diagnosed with Asperger syndrome and hyperkinetic disorder treated with risperidone].
    Monge Galindo L; Escosa García L; García Sánchez N; Ruiz-Lázaro PM
    An Pediatr (Barc); 2009 Jul; 71(1):86-7. PubMed ID: 19473900
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
    Katz IR; Jeste DV; Mintzer JE; Clyde C; Napolitano J; Brecher M
    J Clin Psychiatry; 1999 Feb; 60(2):107-15. PubMed ID: 10084637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone.
    Silver H; Aharon N; Schwartz M
    J Clin Psychopharmacol; 2000 Feb; 20(1):112-4. PubMed ID: 10653224
    [No Abstract]   [Full Text] [Related]  

  • 27. Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.
    Nishimura K; Tsuka M; Horikawa N
    Eur Neuropsychopharmacol; 2001 Aug; 11(4):323-4. PubMed ID: 11532387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases.
    Javelot H; Glay-Ribau C; Ligier F; Weiner L; Didelot N; Messaoudi M; Socha M; Body-Lawson F; Kabuth B
    Ann Pharm Fr; 2014 May; 72(3):164-77. PubMed ID: 24780832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania.
    Carlson T; Reynolds CA; Caplan R
    J Am Acad Child Adolesc Psychiatry; 2007 Mar; 46(3):356-361. PubMed ID: 17314721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Eur J Clin Pharmacol; 2001 Jul; 57(4):327-31. PubMed ID: 11549212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
    Miller DS; Yatham LN; Lam RW
    J Clin Psychiatry; 2001 Dec; 62(12):975-80. PubMed ID: 11780879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms.
    Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Pharmacogenomics J; 2015 Oct; 15(5):452-60. PubMed ID: 25623440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone and tardive dyskinesia.
    Feeney DJ; Klykylo W
    J Am Acad Child Adolesc Psychiatry; 1996 Nov; 35(11):1421-2. PubMed ID: 8936904
    [No Abstract]   [Full Text] [Related]  

  • 34. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
    Bo QJ; Li XB; Wang ZM; Li AN; Ma X; Wang CY
    J Clin Psychopharmacol; 2016 Apr; 36(2):125-9. PubMed ID: 26848792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
    Hollis CP; Thompson A
    Pediatr Neurol; 2007 Oct; 37(4):287-8. PubMed ID: 17903675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
    Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M
    J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
    Tune LE
    J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
    Knable MB; Heinz A; Raedler T; Weinberger DR
    Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.